Back

Revascularization strategy in diffuse versus focal coronary artery stenosis with less than 0,80 fractional flow reserve and impact on outcomes

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Coronary physiology and beyond Fractional Flow Reserve (FFR) ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Carole Chambonnet

HNO Villefranche, Gleize (France)

6 More presentations in this session

Presentation thumbnail
The impact of intravascular ultrasound and optical coherence tomography during percutaneous coronary intervention on clinical outcomes, costs, and readmissions in the USA
Doctor A. Tariq (Orange, US)
Abstract Slides
Presentation thumbnail
Evolution of vasomotor function and myocardial perfusion during three years follow-up after randomization between bioresorbable vascular scaffold and metal drug eluting stent: the VANISH trial
Mr S. Schumacher (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
The predictive value of Pd/pa and resting diastolic pressure ratio (DPR) on 1-year adverse cardiovascular event following contemporary percutaneous coronary intervention
Mr K. Masdjedi (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Vulnerable plaques are revealed by fractional flow reserve but not by instantaneous wave-free ratio
Mr R. Driessen (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
The fractional flow reserve to improve the efficiency of endovascular treatment on left main bifurcation lesions
Associate Professor D. Maximkin (Moscow, RU)
Abstract Slides

Access the full session

Session thumbnail
Coronary physiology and beyond

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
Beyond the stenosis: physiological assessment in modern coronary artery disease management
thumbnail
Congress Presentation
Nuclear cardiology is best for risk assessment
thumbnail
Congress Presentation
Real world impact of added FFR-CT to coronary CT angiography on clinical decision-making and patient prognosis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources